Gentian Diagnostics AS serves the global market with sensitive diagnostic tests. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.
On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’ under the ticker GENT-ME.
Learn more about Gentian Diagnostics AS here.
9TH MAY – ANNUAL REPORT
9TH MAY – QUARTERLY REPORT Q1
28TH MAY – ANNUAL GENERAL MEETING
15TH AUG – HALF–YEARLY REPORT
7TH NOV – QUARTERLY REPORT – Q3
Annual General Meeting for Gentian Diagnostics AS was hold on the 28th of May 2019.
For more information, please see the notice and documents below:
Look at our historical archive to find financial reports and data from 2018, 2017 and 2016.